Will Biomea Fusion announce topline results from the GLP-131 trial of BMF-650 in obesity in otherwise healthy volunteers by October 31, 2026?
deadline 2026-10-31
confidence medium
tier 4 evidence
77%PolySignal estimate
Resolution criterion
Yes if, no later than October 31, 2026, Biomea Fusion publicly reports the topline results of the GLP-131 trial of BMF-650 (the outcome on the primary endpoint, positive or negative) in a press release or SEC filing. The deadline is the last day of the period the company gave in its filing ("October 2026"). An announcement of a delay or of a new timeline, enrollment or interim data that do not report the primary-endpoint outcome, or the absence of any announcement by that date, resolves NO.
Verified starting state
As of October 11, 2026: according to the Biomea Fusion filing of September 22, 2026, the company expects topline results in the period "October 2026". Source: https://www.sec.gov/Archives/edgar/data/1840439/000119312526397870/bmea-20260922.htm
What pushes it up
- Biomea Fusion's SEC filing from September 22, 2026 reiterated expected topline results in 'October 2026', providing very recent official guidance [1].
- There are still 19 days remaining in October 2026 to report the results as planned.
What pushes it down
- Clinical trial data readouts frequently slip past target windows due to routine data cleaning, verification delays, or strategic conference scheduling.
- Almost half of October has passed with no release yet, narrowing the remaining window.
What would move this number most
Whether database lock and final primary-endpoint analysis are completed and approved for disclosure before October 31 or slip into early November.
How this number is built
| Deadline | 2026-10-31 |
| Base rate | 75% |
| Best evidence | tier 4 · 0 article(s) used |
| Independent runs | 75 · 78 (spread 3 pts) |
| Confidence | medium |
| Evidence cap | not triggered |
| Last revised | 2026-10-12 20:00 |
| Model | gemini-3.7-flash |